Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
DBZ (Dibenzazepine) (HB3419)
Description:γ-secretase and Notch pathway inhibitor. Stimulates iPSC formation.
Purity:>99%
3-Deazaneplanocin A hydrochloride (HB1416)
Description:Histone methyltransferase inhibitor. Enhances Oct4 expression in chemically-induced pluripotent stem cells.
Purity:>98%
Dorsomorphin dihydrochloride (HB2800)
Description:Potent, selective AMPK inhibitor. Promotes neural hPSCs differentiation and promotes cardiomyocyte differentiation in mESCs.
Purity:>98%
EHNA hydrochloride (HB3540)
Description:Potent adenosine deaminase and PDE2 inhibitor. Supresses spontaneous hESC differentiation. Also maintains pluripotency of hESCs in the absence of exogenous cytokines.
Purity:>98%
Fluoxetine hydrochloride (HB1600)
Description:Selective 5-HT uptake inhibitor. Affects differentiation of NSCs.
Purity:>98%
Flurbiprofen (HB3049)
Description:Cyclooxygenase inhibitor. Regulates prostate stem cell antigen.
Purity:>99%
Geldanamycin (HB3311)
Description:Selective Hsp90 inhibitor. Breast cancer stem cell inhibitor.
Purity:>98%
Go 6983 (HB0303)
Description:Broad spectrum PKC inhibitor. Optimizes naïve human pluripotent stem cell growth and viability
Purity:>98%
H 89 dihydrochloride (HB0314)
Description:Potent, non-selective kinase inhibitor.Also improves dissociate hESCs survival and clonogenicity.
Purity:>99%